GlassScriptPhysician profile
Ann Marie Hembrough
NPI 1699931725
$9,148.38
in general payments reported to CMS, 2019-2025
29 companies · $3,095 in 2025
The $3,095 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $491 · 2022: $1,116 · 2023: $1,573 · 2024: $2,873 · 2025: $3,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,168 · Education: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,167.66 |
| Education | $373.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,563.10 | 2022-2025 | |
| Janssen Biotech, INC. | $1,189.53 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Galderma Laboratories, L.P. | $943.22 | 2021-2025 | Nemluvio, Aklief, Dysport |
| Regeneron Healthcare Solutions, INC. | $635.16 | 2022-2025 | Dupixent, Libtayo |
| Amgen INC. | $552.58 | 2021-2025 | Otezla, Otezla |
| Lilly USA, LLC | $490.44 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $481.66 | 2021-2025 | Winlevi, Absorica Ld, Blu-U |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $316.78 | 2021-2024 | Cabtreo, Arazlo, Jublia |
| Leo Pharma INC. | $315.75 | 2021-2025 | Adbry |
| Pfizer INC. | $296.90 | 2021-2025 | |
| Journey Medical Corporation | $293.51 | 2021-2025 | |
| Genzyme Corporation | $271.16 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $253.37 | 2023-2025 | Zoryve |
| Incyte Corporation | $249.26 | 2022-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $193.08 | 2022-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $179.97 | 2021 | |
| Novartis Pharmaceuticals Corporation | $158.42 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $151.77 | 2024-2025 | Sotyktu |
| Botanix Sb INC | $110.30 | 2025 | Sofdra |
| Ucb, INC. | $85.12 | 2024-2025 | Bimzelx |
| Almirall LLC | $84.75 | 2023-2025 | Klisyri, Seysara |
| Dermavant Sciences, INC. | $74.50 | 2022-2024 | Vtama |
| Epi Health, LLC | $54.64 | 2021-2022 | |
| Revance Therapeutics, INC. | $53.02 | 2024 | Daxxify |
| Biofrontera INC. | $47.05 | 2021-2025 | |
| Organon LLC | $44.60 | 2025 | Vtama, Nexplanon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.77 | 2022-2023 | Spevigo |
| Genentech USA, INC. | $15.36 | 2023 | Erivedge |
| Convatec INC. | $13.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Marie Hembrough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.